

Cadila gets USFDA nod for Haloperidol Decanoate Injection

24 October 2019 | News

Haloperidol is used in the treatment of schizophrenia



Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited has received the approval from the USFDA for Haloperidol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL, single-dose vials, 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL), multiple-dose vials (US RLD – Haldol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL).

It will be manufactured at Liva Pharma's manufacturing facility at Vadodara.

Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.

The group now has 274 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.